PMCC

**Funding Proposal**

**to**

**Peter Munk Cardiac Centre Innovation Committee**

**Title of Project:**

­­­­­­­­­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Principle Investigator (name, division, e-mail):**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Co-Investigators:**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Date Submitted:**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Overview**

The purpose of this form is to request funding from the Peter Munk Cardiac Centre Innovation Committee for emerging innovative and potentially disruptive (a) technologies or procedures pertaining to cardiac or vascular therapy or (b) techniques, interventions or process improvement for the diagnosis or care of cardiovascular patients or (c) innovative stem cell therapy. Please ensure that all sections of the proposal are completed in detail. Proposals typically range in length from 5 to 10 pages, excluding references and appendices (e.g., quotation or prototype details).

Proposals will be evaluated based on the demonstration of a new and important innovation, the potential to achieve operational efficiency, the potential to improve the quality and efficiency of patient care, the feasibility of implementation, cost benefit per patient and available metrics for measuring success.

This competition is open to any member of the Peter Munk Cardiac Centre at the University Health Network.

**Committee Members**

The committee is made up of both physicians and non-physicians with health care or business expertise:

|  |  |  |
| --- | --- | --- |
| Dr. Harry Rakowski (Chair) | Linda Belford | Dr. Sacha Bhatia |
| Jordan Dermer | Dr. Vlad Dzavik | Dr. Michael Farkouh |
| Angela Feldman | Dr. Kieran Murphy | Jeff Rubenstein |
| Dr. Terry Yau | Marc Lipton | Ronnie Faust |
| Thomas Forbes | Marty Goldfarb | Anthony DiCenzo |

**Funding Envelope and Timelines**

We anticipate that there will be over $1,000,000 per year available for project funding. Funding for innovation will be allocated quarterly. Submission deadlines are:

* January 1
* April 1
* July 1
* October 1

**Submissions**

Send completed form electronically via e-mail to: [dr.harry.rakowski@uhn.ca](mailto:dr.harry.rakowski@uhn.ca) as well as a printed hard copy to Dr. H. Rakowski, 4 North Room 504, Toronto General Hospital.

**Committee Review Process**

Upon receiving the funding request, the committee will review the elements of the proposal within 4-6 weeks following the quarterly submission deadline.

A recommendation will then be made to the PMCC Executive Committee to confirm funding approval. Decision letters will then be e-mailed to the Principal Investigators.

**Parameters**

1. Provide a lay summary for both medical and business reviewers that highlights the innovation, value and goals of the proposal.

* **Mandatory:** Written lay summary (up to 500 words) of the proposal.
* **Optional, but recommended:** 2-minute video that describes a lay summary of the project and potential impact.

1. Describe the initiative and its clinical application and importance.
2. Identify any available literature in support of the application of the proposed initiative.
3. Explain why the initiative is innovative and different than existing options for patient care and how it may improve the quality and/or efficiency of patient care.
4. Describe the funding requirements for the initiative in detail. An example is provided below. Budget justification documents may be attached as appendices.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Indicator | Year 1 | Year 2 | Year 3 | Total |
| Initial start-up cost |  | --- | --- |  |
| Capital cost |  |  |  |  |
| Cost per patient |  |  |  |  |
| Cost of evaluation |  |  |  |  |
| Total |  |  |  |  |

* 1. Are there any other funding sources for this initiative? If so, elaborate.
  2. What is your strategy for sustainable funding? While funding will be considered for up to 3 years, initial funding will only be given for the first year with quarterly progress reports required and resubmission for funding beyond 1 year. There is an expectation that projects for device or technology funding will require application to Health Quality Ontario (HQO) for potential sustained Ministry of Health Funding.

1. If the proposal is for a medical device, indicate device availability and potential suppliers of the technology. Also clarify if the device has been approved for use or is under consideration by Health Canada or any other similar agency in another jurisdiction.
2. Indicate the potential to achieve operational efficiencies (e.g., impact on patient length of stay, impact on process improvements, and impact on readmission rates).
3. Describe the potential for the initiative to improve the patient’s experience and satisfaction.
4. List any planned or potential collaborations with other organizations including potential industry partners. Outline any opportunities for collaboration with multi-centered groups. Indicate the potential for commercialization.
5. Describe the methods (including metrics) used to conduct an outcome assessment.
6. Briefly describe the feasibility of implementing this initiative, the barriers to implementation and likelihood of success, and the time frame to implementation.
7. List any product support and partnerships. If there are other sources of funding please clearly outline the specific application of Innovation funding and the impact of not receiving matching or supporting funds from other sources.
8. Identify centres that are currently using the initiative, nationally or globally.
9. Indicate the status of ethics approval to the Research Ethics Board at UHN.
10. Identify any potential conflicts of interest, or state that no conflicts of interest exist.
11. If there is the potential for commercialization, please indicate the plans for doing so and acknowledge that you will accept UHN rules for profit sharing.